Merck (MRK) Preferred Dividend Payments (2009)
Merck (MRK) posted quarterly Preferred Dividend Payments of -$110.9 million for Q4 2009, down 391.84% quarter-over-quarter from $38.0 million in Q3 2009.
Merck (MRK) Preferred Dividend Payments (2009) Analysis & Trends
Merck (MRK) has reported Preferred Dividend Payments for 1 consecutive years, with -$110.9 million the latest figure, recorded in Q4 2009.
- In Q4 2009, Preferred Dividend Payments changed N/A year-over-year to -$110.9 million; the TTM figure through Dec 2009 stood at -$147.9 million (changed N/A YoY), while the FY2009 annual figure was $2.1 million, changed N/A from the prior year.
- Preferred Dividend Payments slipped to -$110.9 million in Q4 2009 per MRK's latest filing, from $38.0 million in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $38.0 million in Q2 2009 and bottomed at -$110.9 million in Q4 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2009 | -110.90 Mn |
| Sep 30, 2009 | 38.00 Mn |
| Jun 30, 2009 | 38.00 Mn |